Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle Apley, Ph.D., Cory Berkland,…
C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes
